全文获取类型
收费全文 | 18405篇 |
免费 | 1097篇 |
国内免费 | 73篇 |
专业分类
耳鼻咽喉 | 120篇 |
儿科学 | 990篇 |
妇产科学 | 430篇 |
基础医学 | 2607篇 |
口腔科学 | 283篇 |
临床医学 | 1854篇 |
内科学 | 3507篇 |
皮肤病学 | 354篇 |
神经病学 | 1479篇 |
特种医学 | 515篇 |
外科学 | 1916篇 |
综合类 | 360篇 |
一般理论 | 9篇 |
预防医学 | 1615篇 |
眼科学 | 492篇 |
药学 | 1477篇 |
中国医学 | 92篇 |
肿瘤学 | 1475篇 |
出版年
2023年 | 135篇 |
2022年 | 242篇 |
2021年 | 496篇 |
2020年 | 345篇 |
2019年 | 433篇 |
2018年 | 519篇 |
2017年 | 347篇 |
2016年 | 397篇 |
2015年 | 515篇 |
2014年 | 698篇 |
2013年 | 935篇 |
2012年 | 1410篇 |
2011年 | 1493篇 |
2010年 | 789篇 |
2009年 | 697篇 |
2008年 | 1114篇 |
2007年 | 1155篇 |
2006年 | 1049篇 |
2005年 | 1016篇 |
2004年 | 932篇 |
2003年 | 860篇 |
2002年 | 786篇 |
2001年 | 197篇 |
2000年 | 184篇 |
1999年 | 219篇 |
1998年 | 185篇 |
1997年 | 147篇 |
1996年 | 112篇 |
1995年 | 96篇 |
1994年 | 94篇 |
1993年 | 81篇 |
1992年 | 134篇 |
1991年 | 110篇 |
1990年 | 83篇 |
1989年 | 93篇 |
1988年 | 104篇 |
1987年 | 77篇 |
1986年 | 95篇 |
1985年 | 84篇 |
1984年 | 80篇 |
1983年 | 83篇 |
1982年 | 64篇 |
1981年 | 58篇 |
1980年 | 47篇 |
1979年 | 77篇 |
1978年 | 66篇 |
1974年 | 50篇 |
1973年 | 41篇 |
1971年 | 41篇 |
1970年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Lara Silveira Abdo Aguiar Rita de Cssia Rossini Lismary Aparecida de Forville Mesquita Gerson Dellatorre 《Journal of Cosmetic Dermatology》2019,18(6):1733-1736
Depigmented lesions may occur as postinflammatory sequelae of subacute cutaneous lupus erythematosus (SCLE), leading to great psychosocial impact. A 53‐year‐old male patient presented with post‐SCLE depigmented facial lesions after five years of disease stability. We proposed surgical treatment with melanocyte‐keratinocyte transplantation procedure (MKTP), and after five months the patient achieved 90% repigmentation, without Koebner phenomenon (KP). In theory, KP is a possible complication of MKTP procedure since the preparation of the receptor area involves the use of dermabrasion. In an attempt to avoid it, we suggest to maintain the treatment of the underlying disease and wait for a minimum period of disease stability before the procedure. 相似文献
3.
Angela Mauro Salvatore Mauro Roberto Rega Luigi Martemucci Rita Sottile 《Pediatric dermatology》2019,36(1):e34-e36
Henoch‐Schonlein purpura (HSP) is the most common systemic vasculitis in childhood. There is no consensus about the management for isolated cutaneous manifestations in HSP. We describe a case of HSP presenting with severe skin lesions that did not respond to standard therapy with corticosteroids. The 11‐year‐old child was treated with intravenous immunoglobulins, which induced rapid and persistent resolution of symptomatology. 相似文献
4.
Alessia Scarselli Silvia Di Cesare Claudia Capponi Simona Cascioli Maria L. Romiti Gigliola Di Matteo Alessandra Simonetti Paolo Palma Andrea Finocchi Barbarella Lucarelli Rita M. Pinto Ippolita Rana Giuseppe Palumbo Maurizio Caniglia Paolo Rossi Rita Carsetti Caterina Cancrini Alessandro Aiuti 《Journal of clinical immunology》2015,35(4):373-383
5.
6.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
7.
8.
9.
10.